Edgewise Therapeutics details preclinical profile of EDG-7500 cardiac sarcomere modulator in hypertrophic cardiomyopathy

Edgewise Therapeutics outlined the preclinical profile for EDG-7500, a first-in-class cardiac sarcomere modulator for symptomatic hypertrophic cardiomyopathy.

• Results have already been generated in preclinical models; a peer-reviewed paper detailing the mechanism is scheduled for release later today.
• Data indicate improved cardiac relaxation while preserving overall pumping performance, supporting a diastolic-focused approach without apparent functional trade-offs.
• Early clinical observations in symptomatic hypertrophic cardiomyopathy patients were described as consistent with the preclinical findings.
• Management is set to discuss the findings in an investor webcast today at 8:30 a.m. ET.